There are well-established, significant ethical concerns regarding the safety and efficacy of treatments offered by stem cell clinics. Much less is known about those actually providing these unproven interventions. Now, researchers have collected data about their background and training.
A low patient safety score at an Atlanta hospital spurred Piedmont Healthcare to revamp infection control systemwide, leading to dramatic improvements that included reducing catheter-associated urinary tract infections by 65% over two years.
Scientists are now investigating a nonhormonal monthly ring (Ovaprene) as a potential contraceptive. The device involves a permeable mesh in the center of the ring that creates a partial barrier to sperm and locally acting spermiostatic agents to create an inhospitable environment for sperm.
Researchers are evaluating a vaginal ring designed to protect women against both HIV and herpes simplex virus type 2 in a Phase I study. The trial is being conducted by researchers from the National Institutes of Health-funded Microbicide Trials Network at three U.S. sites in Alabama, California, and Pennsylvania.
In an effort to provide both HIV/AIDS and unintended pregnancy protection, researchers have developed a vaginal ring containing the antiretroviral drug dapivirine and the contraceptive hormone levonorgestrel. Scientists have just released results of an initial clinical trial, noting no safety issues.
International pharmaceutical company Bayer has announced that it will cease U.S. sales of its Essure sterilization device as of December 2018. Although the company is halting distribution because of declining sales, the decision comes amid mounting concerns surrounding its use.